

6. Quellenverzeichnis

1. **Sakano,H., Kurosawa,Y., Weigert,M., and Tonegawa,S.,** Identification and nucleotide sequence of a diversity DNA segment (D) of immunoglobulin heavy-chain genes. *Nature* 1981. **290**: 562-565.
2. **Alt,F.W. and Baltimore,D.,** Joining of immunoglobulin heavy chain gene segments: implications from a chromosome with evidence of three D-JH fusions. *Proc.Natl.Acad.Sci.U.S.A* 1982. **79**: 4118-4122.
3. **Berek,C., Berger,A., and Apel,M.,** Maturation of the immune response in germinal centers. *Cell* 1991. **67**: 1121-1129.
4. **Jacob,J., Kelsoe,G., Rajewsky,K., and Weiss,U.,** Intracloal generation of antibody mutants in germinal centres. *Nature* 1991. **354**: 389-392.
5. **Lang,D.J., Garruto,R.M., and Gajdusek,D.C.,** Early acquisition of cytomegalovirus and Epstein-Barr virus antibody in several isolated Melanesian populations. *Am.J.Epidemiol.* 1977. **105**: 480-487.
6. **Henle,G., Henle,W., and Diehl,V.,** Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. *Proc.Natl.Acad.Sci.U.S.A* 1968. **59**: 94-101.
7. **Purtilo,D.T., Cassel,C.K., Yang,J.P., and Harper,R.,** X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). *Lancet* 1975. **1**: 935-940.
8. **Saemundsen,A.K., Purtilo,D.T., Sakamoto,K., Sullivan,J.L., Synnerholm,A.C., Hanto,D., Simmons,R., Anvret,M., Collins,R., and Klein,G.,** Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. *Cancer Res.* 1981. **41**: 4237-4242.
9. **Klein,G. and Klein,E.,** Evolution of tumours and the impact of molecular oncology. *Nature* 1985. **315**: 190-195.
10. **Cheeseman,S.H.,** Infectious mononucleosis. *Semin.Hematol.* 1988. **25**: 261-268.
11. **Childs,C.C., Parham,D.M., and Berard,C.W.,** Infectious mononucleosis. The spectrum of morphologic changes simulating lymphoma in lymph nodes and tonsils. *Am.J.Surg.Pathol.* 1987. **11**: 122-132.

12. **Foss,H.D., Herbst,H., Hummel,M., Araujo,I., Latza,U., Rancso,C., Dallenbach,F., and Stein,H.,** Patterns of cytokine gene expression in infectious mononucleosis. *Blood* 1994. **83**: 707-712.

13. **Anagnostopoulos,I., Hummel,M., Kreschel,C., and Stein,H.,** Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. *Blood* 1995. **85**: 744-750.

14. **Epstein,M.A., Achong,B.G., and Barr,Y.M.,** VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. *Lancet* 1964. **15**: 702-703.

15. **Greenspan,J.S., Greenspan,D., Lennette,E.T., Abrams,D.I., Conant,M.A., Petersen,V., and Freese,U.K.,** Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. *N.Engl.J.Med.* 1985. **313**: 1564-1571.

16. **Ziegler,J.L., Drew,W.L., Miner,R.C., Mintz,L., Rosenbaum,E., Gershow,J., Lennette,E.T., Greenspan,J., Shillitoe,E., Beckstead,J., Casavant,C., and Yamamoto,K.,** Outbreak of Burkitt's-like lymphoma in homosexual men. *Lancet* 1982. **2**: 631-633.

17. **Rickinson,A.B., Young,L.S., and Rowe,M.,** Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. *J.Virol.* 1987. **61**: 1310-1317.

18. **Baer,R., Bankier,A.T., Biggin,M.D., Deininger,P.L., Farrell,P.J., Gibson,T.J., Hatfull,G., Hudson,G.S., Satchwell,S.C., Seguin,C., and .,** DNA sequence and expression of the B95-8 Epstein-Barr virus genome. *Nature* 1984. **310**: 207-211.

19. **Ling,P.D., Rawlins,D.R., and Hayward,S.D.,** The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. *Proc.Natl.Acad.Sci.U.S.A* 1993. **90**: 9237-9241.

20. **Johannsen,E., Koh,E., Mosialos,G., Tong,X., Kieff,E., and Grossman,S.R.,** Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. *J.Virol.* 1995. **69**: 253-262.

21. **Kieff E,** Epstein-Barr virus and its replication. In **Fields BN, Knipe DM, and Howley PM** (Eds.) *Fields virology*. Philadelphia: Lippincott-Raven, 1996, pp 2343-2396.

22. **Wang,D., Liebowitz,D., and Kieff,E.,** An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. *Cell* 1985. **43**: 831-840.

23. **Kaye,K.M., Izumi,K.M., and Kieff,E.,** Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. *Proc.Natl.Acad.Sci.U.S.A* 1993. **90**: 9150-9154.

24. **Mosialos,G., Birkenbach,M., Yalamanchili,R., VanArsdale,T., Ware,C., and Kieff,E.,** The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. *Cell* 1995. **80**: 389-399.

25. **Kaye,K.M., Devergne,O., Harada,J.N., Izumi,K.M., Yalamanchili,R., Kieff,E., and Mosialos,G.,** Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. *Proc.Natl.Acad.Sci.U.S.A* 1996. **93**: 11085-11090.

26. **Devergne,O., Hatzivassiliou,E., Izumi,K.M., Kaye,K.M., Kleijnen,M.F., Kieff,E., and Mosialos,G.,** Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. *Mol.Cell Biol.* 1996. **16**: 7098-7108.

27. **Liebowitz,D., Mannick,J., Takada,K., and Kieff,E.,** Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells. *J.Virol.* 1992. **66**: 4612-4616.

28. **Wang,C., Ai,M., Ren,W., Xiao,H., Li,X., Tang,F., Gu,H., Yi,W., Weng,X., Deng,X., and Cao,Y.,** Epstein-Barr virus encoded latent membrane protein 1 induces TRAF1 expression to promote anti-apoptosis activity via NF-kappaB signaling pathway in nasopharyngeal carcinoma. *Chin Med.J (Engl.)* 2003. **116**: 1022-1028.

29. **van Kooten,C. and Banchereau,J.,** Functions of CD40 on B cells, dendritic cells and other cells. *Curr.Opin.Immunol.* 1997. **9**: 330-337.

30. **Hammarskjold,M.L. and Simurda,M.C.,** Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity. *J.Virol.* 1992. **66**: 6496-6501.

31. **Lerner,M.R., Andrews,N.C., Miller,G., and Steitz,J.A.,** Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. *Proc.Natl.Acad.Sci.U.S.A* 1981. **78**: 805-809.

32. **Howe,J.G. and Steitz,J.A.,** Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization. *Proc.Natl.Acad.Sci.U.S.A* 1986. **83**: 9006-9010.

33. **Ruf,I.K., Rhyne,P.W., Yang,C., Cleveland,J.L., and Sample,J.T.,** Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. *J.Virol.* 2000. **74**: 10223-10228.

34. **Toczyski,D.P. and Steitz,J.A.,** EAP, a highly conserved cellular protein associated with Epstein-Barr virus small RNAs (EBERs). *EMBO J.* 1991. **10**: 459-466.

35. **Fingerroth,J.D., Weis,J.J., Tedder,T.F., Strominger,J.L., Biro,P.A., and Fearon,D.T.,** Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. *Proc.Natl.Acad.Sci.U.S.A* 1984. **81**: 4510-4514.
36. **Nemerow,G.R., Houghten,R.A., Moore,M.D., and Cooper,N.R.,** Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). *Cell* 1989. **56**: 369-377.
37. **Miller,G.,** The switch between latency and replication of Epstein-Barr virus. *J.Infect.Dis.* 1990. **161**: 833-844.
38. **Alfieri,C., Birkenbach,M., and Kieff,E.,** Early events in Epstein-Barr virus infection of human B lymphocytes. *Virology* 1991. **181**: 595-608.
39. **Kerr,B.M., Lear,A.L., Rowe,M., Croom-Carter,D., Young,L.S., Rookes,S.M., Gallimore,P.H., and Rickinson,A.B.,** Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. *Virology* 1992. **187**: 189-201.
40. **Tierney,R.J., Steven,N., Young,L.S., and Rickinson,A.B.,** Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. *J.Virol.* 1994. **68**: 7374-7385.
41. **Wang,F., Gregory,C., Sample,C., Rowe,M., Liebowitz,D., Murray,R., Rickinson,A., and Kieff,E.,** Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. *J.Virol.* 1990. **64**: 2309-2318.
42. **Young,L.S., Lau,R., Rowe,M., Niedobitek,G., Packham,G., Shanahan,F., Rowe,D.T., Greenspan,D., Greenspan,J.S., Rickinson,A.B., and ,** Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. *J.Virol.* 1991. **65**: 2868-2874.
43. **de The,G., Geser,A., Day,N.E., Tukei,P.M., Williams,E.H., Beri,D.P., Smith,P.G., Dean,A.G., Bronkamm,G.W., Feorino,P., and Henle,W.,** Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. *Nature* 1978. **274**: 756-761.
44. **Araujo,I., Foss,H.D., Bittencourt,A., Hummel,M., Demel,G., Mendonca,N., Herbst,H., and Stein,H.,** Expression of Epstein-Barr virus-gene products in Burkitt's lymphoma in Northeast Brazil. *Blood* 1996. **87**: 5279-5286.
45. **zur,H.H., Schulte-Holthausen,H., Klein,G., Henle,W., Henle,G., Clifford,P., and Santesson,L.,** EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. *Nature* 1970. **228**: 1056-1058.

46. **Sixbey,J.W., Nedrud,J.G., Raab-Traub,N., Hanes,R.A., and Pagano,J.S.,** Epstein-Barr virus replication in oropharyngeal epithelial cells. *N.Engl.J.Med.* 1984. **310**: 1225-1230.
47. **Niedobitek,G., Young,L.S., Lau,R., Brooks,L., Greenspan,D., Greenspan,J.S., and Rickinson,A.B.,** Epstein-Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase. *J.Gen.Virol.* 1991. **72 (Pt 12)**: 3035-3046.
48. **Herbst,H., Niedobitek,G., Kneba,M., Hummel,M., Finn,T., Anagnostopoulos,I., Bergholz,M., Krieger,G., and Stein,H.,** High incidence of Epstein-Barr virus genomes in Hodgkin's disease. *Am.J.Pathol.* 1990. **137**: 13-18.
49. **Weiss,L.M., Movahed,L.A., Warnke,R.A., and Sklar,J.,** Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. *N.Engl.J Med.* 1989. **320**: 502-506.
50. **Hummel,M., Anagnostopoulos,I., Korbjuhn,P., and Stein,H.,** Epstein-Barr virus in B-cell non-Hodgkin's lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types. *J.Pathol.* 1995. **175**: 263-271.
51. **Karajannis,M.A., Hummel,M., Anagnostopoulos,I., and Stein,H.,** Strict lymphotropism of Epstein-Barr virus during acute infectious mononucleosis in nonimmunocompromised individuals. *Blood* 1997. **89**: 2856-2862.
52. **Niedobitek,G. and Young,L.S.,** Epstein-Barr virus persistence and virus-associated tumours. *Lancet* 1994. **343**: 333-335.
53. **Babcock,G.J., Decker,L.L., Volk,M., and Thorley-Lawson,D.A.,** EBV persistence in memory B cells in vivo. *Immunity.* 1998. **9**: 395-404.
54. **Miyashita,E.M., Yang,B., Babcock,G.J., and Thorley-Lawson,D.A.,** Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. *J.Virol.* 1997. **71**: 4882-4891.
55. **Kurth,J., Spieker,T., Wustrow,J., Strickler,G.J., Hansmann,L.M., Rajewsky,K., and Kuppers,R.,** EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. *Immunity.* 2000. **13**: 485-495.
56. **Babcock,G.J., Hochberg,D., and Thorley-Lawson,A.D.,** The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. *Immunity.* 2000. **13**: 497-506.
57. **Stein,K., Hummel,M., Korbjuhn,P., Foss,H.D., Anagnostopoulos,I., Marafioti,T., and Stein,H.,** Monocytoid B cells are distinct from splenic marginal zone cells and commonly derive from unmutated naive B cells and less frequently from postgerminal center B cells by polyclonal transformation. *Blood* 1999. **94**: 2800-2808.

58. **Araujo,I., Foss,H.D., Hummel,M., Anagnostopoulos,I., Barbosa,H.S., Bittencourt,A., and Stein,H.,** Frequent expansion of Epstein-Barr virus (EBV) infected cells in germinal centres of tonsils from an area with a high incidence of EBV-associated lymphoma. *J.Pathol.* 1999. **187**: 326-330.
59. **Pascual,V., Liu,Y.J., Magalski,A., de Bouteiller,O., Banchereau,J., and Capra,J.D.,** Analysis of somatic mutation in five B cell subsets of human tonsil. *J.Exp.Med.* 1994. **180**: 329-339.
60. **Gires,O., Zimber-Strobl,U., Gonnella,R., Ueffing,M., Marschall,G., Zeidler,R., Pich,D., and Hammerschmidt,W.,** Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. *EMBO J.* 1997. **16**: 6131-6140.
61. **Brauninger,A., Spieker,T., Willenbrock,K., Gaulard,P., Wacker,H.H., Rajewsky,K., Hansmann,M.L., and Kuppers,R.,** Survival and clonal expansion of mutating "forbidden" (immunoglobulin receptor-deficient) epstein-barr virus-infected b cells in angioimmunoblastic t cell lymphoma. *J.Exp.Med.* 2001. **194**: 927-940.